Diabetes Dialogue: 2023 Top Episodes Recap

Few, if any, fields in medicine have captivated the attention of public health as diabetes management in 2023. Although the majority of this attention has come as the result of pharmacologic advances, such as teplizumab in type 1 diabetes, and revelations surrounding the potential of incretin therapies, the field has celebrated a multitude of advances in the past year—from new guidelines to novel approvals and groundbreaking advances in technology.

Throughout 2023, HCPLive’s flagship endocrinology podcast Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives has chronicled top news and developments across the field. Hosted by Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, the podcast has launched more than 45 new episodes in the past year.

To celebrate the year in diabetes management, HCPLive Endocrinology presents a recap episode where hosts reflect on the top 10 most popular episodes from the year and how the subjects of each have shaped the future of diabetes management.

Below is a list of episodes discussed in the recap, beginning with no. 10 and ending with 2024’s most popular:

• Automated Insulin Delivery News in October 2023 (00:32)
• Breaking Down AACE's New Type 2 Diabetes Management Algorithms (04:35)
• What Medicare Drug Price Negotiations Mean for Diabetes (06:45)
• STEP-HFpEF Reaction (09:15)
  • Related: SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023
• Dexcom G7 and the Future of CGM, with Jake Leach (12:10)
• Tandem Mobi and Welldoc's BlueStar Platform (13:20)
• Making Sense of Semaglutide in Type 1 Diabetes (16:20)
• Establishing Time in Range as a Primary Glucose Metric (18:35)
• TRANSITION-T2D, with Paloma Rodriguez, MD, and Kevin Pantalone, DO (21:15)
• What to Know about the iLet Bionic Pancreas (25:15)
  • Related: The Prospect of a Bionic Pancreas, with Steven Russell, MD, PhD

Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.